drugset / Trial / NCT02084069

Atrovastatin for Preventing Atrial Fibrillation Following Open Cardiac Valve Repair

NCT02084069 ↗

Phase 3 Completed 58 enrolled Urmia University of Medical Sciences
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of the investigation is to determine whether Atrovastatin as anti-inflammatory agent can be effective in preventing from atrial fibrillation incidence in patients whom undergone open cardiac surgery for their heart valve repair.

Timeline

Start
2013-01
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 40 mg —

Indications